Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 09:01 ET | Source: Research and Markets

DLL3-Targeted Immunotherapy Competitor Analysis Report 2025: The Field Still is in Mid-stage Clinical Development Without Clear Leader in the Competition

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "DLL3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 09:00 ET | Source: Research and Markets

B7-H3-Targeted Immunotherapy Competitor Analysis Report 2025: More Than 15 Product Candidates are in Clinical Development, with Several Already in Clinical Phase III

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:58 ET | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:54 ET | Source: Research and Markets

Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Competitive Intelligence Report 2025: Launch of the First Tocilizumab Biosimilar Antibodies Highlights the Attractiveness of the Market

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive...
November 27, 2025 08:45 ET | Source: Research and Markets

NaPi2b-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of NaPi2b-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:43 ET | Source: Research and Markets

KLK2-Targeted Immunotherapies Pipeline Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of KLK2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:42 ET | Source: Research and Markets

STEAP1- and STEAP2-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
November 27, 2025 08:40 ET | Source: Research and Markets

Tissue Factor-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Tivdak Has Become the Benchmark for Improved Next Generation ADCs in Non-clinical and Clinical Development

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Tissue Factor-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:18 ET | Source: Research and Markets

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline and Competitive Intelligence Report 2025: Oncology Applications Using Biomarker-driven Patient Stratification and Combination Treatments

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 21, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...